Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison-Reference-Cited by-同舟云学术

Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison

Published:2021-05 Issue: Volume:155 Page:175-182
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Halmos Balazs,Burke Thomas,Kalyvas Chrysostomos^ORCID,Vandormael Kristel,Frederickson Andrew,Piperdi Bilal

Funder

Merck and Co Inc

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. Non-small cell lung cancer: current treatment and future advances;Zappa;Transl. Lung Cancer Res.,2016

3. The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer;Low;Ther. Adv. Med. Oncol.,2019

4. The biology and management of non-small cell lung cancer;Herbst;Nature,2018

5. Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?;Gravara;Lung Cancer Manage.,2020

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release;Journal of Managed Care & Specialty Pharmacy;2024-06

2. Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2024-05-03

3. Validation of an enzyme-linked immunosorbent assay test-system for bevacizumab concentration determing in biological fluids;Drug development & registration;2024-04-26

4. Overview of drugs approved by the FDA in 2022;Pharmacy & Pharmacology;2023-11-20

5. Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer;Journal of Cancer Research and Clinical Oncology;2023-11-17